Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001829126-23-003608
Filing Date
2023-05-19
Accepted
2023-05-19 09:30:55
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A titanpharma_defa14a.htm DEFA14A 14776
2 GRAPHIC proxy_001.jpg GRAPHIC 210122
3 GRAPHIC proxy_002.jpg GRAPHIC 202885
  Complete submission text file 0001829126-23-003608.txt   584800
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-13341 | Film No.: 23938135
SIC: 2836 Biological Products, (No Diagnostic Substances)